Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.32 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485038 | 1.00 | HTR6 (0.50) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6700639 | 1.00 | HTR6 (0.50) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL38659074 | 0.98 | HTR6 (0.48) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| Ammonia Solution, Strong SCHEMBL19410112 | 0.98 | HTR6 (0.48) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL2200285 | 0.98 | HTR6 (0.48) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL2200278 | 0.98 | HTR6 (0.48) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| Bromide SCHEMBL1307460 | 0.98 | HTR6 (0.48) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL31209302 | 0.92 | HTR6 (0.53) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL22527614 | 0.92 | HTR6 (0.53) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL18123339 | 0.88 | HTR6 (0.57) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2025-05-15 | — | — | US | disclosed |
| EP-4395892-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118302426-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023034812-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023034812-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-2483277-B1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-12-02 | — | — | EP | disclosed |
| CN-102762574-B | Benzoxapi 3K inhibitor compounds and methods of use | HOFFMAN-LA ROCHE LTD. (CH) | 2015-12-02 | — | — | CN | disclosed |
| US-9175009-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| CN-104987345-A | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE | 2015-10-21 | — | — | CN | disclosed |
| US-20140135308-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8673952-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2013-01-10 | — | — | US | disclosed |
| CN-102762574-A | Benzoxapi 3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE | 2012-10-31 | — | — | CN | disclosed |
| US-8263633-B2 | Benzoxepin PI3K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2483277-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2011036284-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R2 | HTR6 4038/4885SMN1; SMN2 2293/4885PIK3CD 2/4885 |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | HTR6 3441/4885SMN1; SMN2 1519/4885PIK3CD 70/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | HTR6 346/4885SMN1; SMN2 2633/4885PIK3CD 2841/4885 |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | HTR6 2732/4885SMN1; SMN2 301/4885PIK3CD 3109/4885 |
| US-20140135308-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | HTR6 3441/4885SMN1; SMN2 1519/4885PIK3CD 70/4885 |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | HTR6 1239/4885SMN1; SMN2 4326/4885PIK3CD 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.